196 results about "Metformin" patented technology

The invention discloses an anti-tumor intelligent double-crosslinking hydrogel drug delivery system based on a purple phosphorus nanosheet and a preparation method and application thereof, the system comprises a hydrogel carrier, a photodynamic carrier material and a drug, and the hydrogel carrier is a drug delivery carrier formed by crosslinking polydimethyldiguanide with Fe < 3 + > and a crosslinking agent; the photodynamic carrier material is a purple phosphorus nanosheet; the medicine is a medicine with two effects of inhibiting hypoxia-inducible factor-1 alpha and lowering PD-L1 down. According to the invention, the purple phosphorus nanosheet and the polydimethyldiguanide / Fe < 3 + > bi-crosslinking hydrogel are taken as carriers to prepare the tumor microenvironment response type hydrogel drug delivery system with good pH responsiveness, injectability and self-healing property, so that an effective solution is provided for tumor precise drug delivery mediated by a new material, namely the purple phosphorus nanosheet, as a nano-drug carrier; the invention also provides an effective photodynamic therapy strategy for anti-tumor application of the intelligent double-crosslinking hydrogel and precise treatment of breast cancer.

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

The invention relates to the technical field of biomedical materials, in particular to photo-thermal antibacterial healing-promoting hydrogel as well as a preparation method and application thereof. The preparation method of the hydrogel comprises the following steps: dispersing mesoporous polydopamine (MPDA) into a Tris-HCl solution, and then adding L-arginine to prepare L-MPDA; the preparation method comprises the following steps: fully dissolving 3-(aminomethyl) phenylboronic acid hydrochloride and 4-(4, 6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride into hyaluronic acid (HA), regulating the pH value to 6.5 by using alkali liquor to obtain phenylboronic acid modified hyaluronic acid mixed liquor, and dialyzing and freeze-drying to obtain HA-PBA. The preparation method comprises the following steps: dissolving metformin and purified L-MPDA in deionized water, sequentially adding purified HA-PBA and a polyvinyl alcohol (PVA) solution, and uniformly mixing to obtain the hydrogel. The hydrogel prepared by the invention has excellent hemostasis, antibacterial and adhesion properties. When the hydrogel is used as a hydrogel dressing for treating a diabetic wound surface, the healing speed of the diabetic wound surface can be effectively improved.

The invention discloses a hypoglycemic composition containing supramolecular group composite peptide. The hypoglycemic composition comprises collagen peptide, soybean peptide, bitter gourd peptide, bamboo leaf flavone, L-carnitine and the like. The composition prepared by selecting raw material components of specific types and dosages has the effects of remarkably reducing the glucose level and increasing the insulin level, and part of the composition can also cooperate with metformin to achieve the effects of enhancing the effect of reducing blood sugar and improving or preventing type 2 diabetes mellitus. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The invention discloses an application of an AMPK (adenosine monophosphate kinase) activator or a PPAR (peroxisome proliferator activated receptor) gamma inhibitor in preparation of a medicine for preventing or treating diabetic osteoporosis. The invention discloses a key effect of a brand new signal channel, namely an AMPK-PPAR gamma-ERS axis, in osteogenic differentiation disorder of diabetes mellitus, and provides a method for preventing and treating diabetic osteoporosis by regulating and controlling the signal axis by taking metformin as a core. The invention provides new guidance for research and development of medicines for treating osteoporosis, and has potential clinical application and mechanism research values.

The invention discloses composite hydrogel and application of the composite hydrogel in preparation of a diabetes wound repair dressing. The gel comprises Metformin (Met) loaded Mg-MOF / Met nano-particles, a hydrogel carrier and a hydrogel carrier, wherein the Mg-MOF / Met nano-particles are prepared from the following components of Mg-MOF / Met nano-particles; the hydrogel network is formed by cross-linking chitosan (CA) modified by arginine and oxidized dextran through a Schiff base reaction; wherein the Mg-MOF / Met nano particles are uniformly dispersed in the hydrogel network, and the Mg-MOF / Met nano particles are uniformly dispersed in the hydrogel network. An animal model verifies that after 14 days, the healing rate reaches 92.1%, the antibacterial rate is larger than 95%, the ROS clearance rate is 85.2%, the cell survival rate is larger than 95%, and remarkable application prospects are shown in the field of diabetes wound repair.

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

The present invention relates to the field of pharmaceutical technology, and in particular to a pioglitazone hydrochloride and metformin compound tablet and a preparation method thereof. The pharmaceutical preparation utilizes ultrasonic technology in combination with a solubility regulator to improve the solubility of pioglitazone hydrochloride, thereby preparing an excellent pioglitazone hydrochloride solid dispersion. The suspension is further prepared and coated around a metformin tablet core by a suspension-loading method. In the present invention, the preparation of the pioglitazone hydrochloride solid dispersion and the loading method are key factors affecting the solubility and uniformity of pioglitazone hydrochloride and metformin. By further optimizing the formulation, controlling the granulation process conditions, and coordinating the solubility of metformin and pioglitazone hydrochloride, a compound tablet with good compounding effect is obtained. The prepared compound tablet has good uniformity, thereby achieving uniform drug dispersion and controlled release.

The invention discloses application of metformin to improvement of crop seed germination and stress resistance, the metformin is used as a widely used hypoglycemic drug, has a cross-species conservative metabolism regulation function, can activate an antioxidant defense system of plants, maintain K < + > / Na < + > balance in the plants, and can improve the survivability of crops in saline-alkali soil. After the metformin is adopted to treat the seeds, the germination rate and the germination potential of the seeds are obviously improved, the chlorophyll content, the peroxidase content, the soluble protein content and the like of seedlings are obviously increased, the malondialdehyde content is obviously reduced, and the stress resistance is obviously enhanced. The technology is low in treatment cost, simple to operate and obvious in effect.

The utility model discloses a metformin hydrochloride electrochemical analysis device which comprises a shell, and one side of the shell is provided with an electric sensor interface; the power supply unit is arranged in the shell and is used for generating polarization voltage; the silk-screen printing electrode electric sensor is electrically connected with the power supply unit and comprises a flexible electrode base body, a working electrode, a counter electrode, a reference electrode, an insulating layer, a wiring terminal and an electrode connecting wire, and the working electrode, the counter electrode, the reference electrode, the insulating layer, the wiring terminal and the electrode connecting wire are arranged on the flexible electrode base body; the surface of the working electrode is modified with an imprinted polymer with selective recognition on metformin hydrochloride; the signal processing unit is arranged in the shell and comprises a shunt resistor, an operational amplifier, a signal converter, a data storage chip and a microprocessor which are electrically connected in sequence; the display screen is electrically connected with the microprocessor and is used for displaying the converted concentration value; the method has the advantages that the metformin hydrochloride can be rapidly and accurately detected, and the use is relatively convenient.

The application belongs to the technical field of bioactive nanomaterials, and particularly relates to a metformin nanomaterial, a preparation method and application thereof. The average hydrodynamic diameter of the nanomaterial is less than 500 nm, and the nanomaterial is prepared by a preparation method comprising the following steps: self-assembly of metformin and polyphenols to obtain metformin-polyphenol nanoparticles; reaction of bisphosphonate and polyethylene glycol to obtain bisphosphonate-polyethylene glycol organic segments; and reaction of the metformin-polyphenol nanoparticles and the bisphosphonate-polyethylene glycol organic segments to obtain the nanomaterial. The metformin, polyphenol, polyethylene glycol and bisphosphonate are prepared into the metformin-loaded nanomaterial through specific reactions, the systemic delivery of metformin is realized, the efficacy and bioavailability of metformin on osteoporosis are improved, and the bone targeting of metformin is also improved.

A single-layer tablet comprising linagliptin, or a pharmaceutically acceptable salt thereof, metformin hydrochloride, a diluent, a glidant and a lubricant, wherein the tablet is produced by direct compression.

The application discloses a preparation method of CCR2+ gamma delta T cells with anti-tumor activity and migration ability, and belongs to the technical field of cells; the method comprises the following steps: step (1), PBMC of peripheral blood of a healthy person is extracted, inoculated into complete culture medium, and added with zoledronic acid, IL-15 and metformin, and then is cultured in a T25 culture bottle; step (2), complete culture medium is supplemented, the cell concentration is adjusted, and then the cells are transferred into a T75 culture bottle for culture; step (3), complete culture medium is supplemented, the cell concentration is adjusted, glucocorticoid and nicotinamide are added, and then the cells are transferred into a T150 culture bottle for culture; step (4), cells are collected at D6, rinsed with normal saline, resuspended with complete culture medium, the cell concentration is adjusted, and then the cells are inoculated into a T300 culture bottle for culture; and step (5), complete culture medium is supplemented every two days from D8 to D16, the cell concentration is maintained, and then the cells are harvested at D16 to obtain CCR2+ gamma delta T cells.

Compositions and methods are provided for the prevention of osteonecrosis or osteoporosis associated with corticosteroid administration in an individual. The methods of the disclosure comprise administration of an effective dose of a metformin agent, or a derivative, mimetic or analog thereof in combination with administration of a corticosteroid. The effective dose of metformin agent decreases oxidative stress and restores osteogenic capacity of mesenchymal stem cells exposed to a glucocorticoid.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

The invention relates to a linagliptin and metformin sustained-release composition and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the linagliptin and metformin sustained-release composition comprises a metformin sustained-release tablet core and a linagliptin coating layer wrapping the metformin sustained-release tablet core; the linagliptin coating layer accounts for 2-3% of the total mass of the composition; the metformin sustained-release tablet core comprises a plain pellet core, a coating layer and a filling agent; wherein the plain pellet core comprises a large-particle-size pellet core of 1.10-1.25 mm, a medium-particle-size pellet core of 0.80-0.95 mm and a small-particle-size pellet core of 0.50-0.65 mm, and the mass ratio of the large-particle-size pellet core to the medium-particle-size pellet core to the small-particle-size pellet core is 15: 60: 25; through particle size grading, pore differentiation design and hydrophobic modification treatment, the drug release curve is optimized, the release uniformity is improved, and meanwhile, the production stability and the consistency of the preparation are improved.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The present invention relates to a method for obtaining sustained release metformin mini-tablets, to the mini-tablets obtainable by this method, and to the use of these mini-tablets as monotherapy or in combination with other active pharmaceutical agents.

The invention relates to the technical field of analytical chemistry, in particular to a method for detecting metformin based on gold nano-cluster fluorescent test paper. In order to solve the problem of inconvenience in metformin detection, the invention provides the following technical scheme: the method comprises the following steps: S1, preparing an ATT-AuNCs solution; s2, preparing gold nano-cluster fluorescent test paper; s3, constructing a metformin detection standard curve; S31, preparing a metformin concentration gradient solution; s33, performing signal processing and curve fitting; s4, detecting metformin in a to-be-detected sample; S41, pretreating the sample; s42, test paper detection and signal acquisition; and S43, calculating the concentration. The ATT-AuNCs gold nano-cluster adopted by the invention has the remarkable advantages of strong photoluminescence performance, large Stokes shift, good biocompatibility, easiness in synthesis and surface modification and the like, the fluorescent test paper constructed based on the gold nano-cluster is convenient to carry, the detection of metformin can be realized only by virtue of an ultraviolet lamp, large-scale instruments and equipment are not needed, and the cost is low. The method is simple and rapid, has visual results, and can be used for determining metformin in drugs and health care products.

The invention relates to a dapagliflozin and metformin sustained-release tablet and a preparation method thereof, corresponding anti-spallation stabilizers are respectively added into dapagliflozin and metformin layer materials in a prescription, and the problems of temperature, humidity and spallation generated in the storage process can be reduced.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

The invention discloses a synthesis method of a fullerene nano material with glycolipid metabolism regulation capability, and belongs to the technical field of material science and biomedical engineering. The fullerene and the metformin are combined through chemical bonds, the strong oxidation resistance of the fullerene and the hypoglycemic effect of the metformin are exerted at the same time, the synergistic treatment effect is formed, and the drug composition is superior to a single drug; active oxygen in cells can be efficiently removed, oxidative stress is effectively relieved, and the functions of pancreatic beta cells are protected; through structural modification, the problem of low bioavailability caused by hydrophobicity of fullerene and hydrophilicity of metformin is solved, and the solubility and absorption efficiency of the medicine are improved; in conclusion, through chemical combination of the fullerene and the metformin, a dual-mechanism synergistic effect of oxidation resistance and blood sugar reduction is achieved, the treatment effect is remarkably improved, meanwhile, good safety and biocompatibility are achieved, and important application value is achieved in the field of treatment of the type II diabetes mellitus.

The application discloses a metformin-induced stem cell-derived extracellular matrix material and a preparation method and application thereof, and relates to the technical field of biological materials. The preparation method comprises the following steps: inoculating mesenchymal stem cells on a pretreated culture carrier, and using a culture system containing metformin to induce and treat the mesenchymal stem cells; adding ascorbic acid to induce and culture extracellular matrix secretion; carrying out decellularization treatment and nuclease treatment on the metformin-induced extracellular matrix; collecting the metformin-induced stem cell-derived extracellular matrix, mixing the metformin-induced stem cell-derived extracellular matrix with an aqueous medium, and enriching and forming an extracellular matrix precipitate through centrifugal treatment; and sequentially carrying out freezing treatment and thawing treatment on the extracellular matrix precipitate to obtain the metformin-induced stem cell-derived extracellular matrix material. The metformin is used to induce the mesenchymal stem cells to secrete an engineered extracellular matrix, and the engineered extracellular matrix is used to promote the repair of bone defects, skeletal muscle injuries and musculoskeletal joint defects in a diabetic environment.

The present disclosure provides a preparation method for metformin hydrochloride. The preparation method includes: microwave heating raw materials containing dicyandiamide and dimethylamine hydrochloride, and reacting the two at 100° C. to 160° C. to obtain a product system containing metformin hydrochloride. Microwave heating is adopted to heat the dicyandiamide and the dimethylamine hydrochloride. Compared with a conventional heating mode that requires heat to be gradually transferred from the outside to the inside, microwave heating can directly heat each part inside the reactant, which can make the internal temperature of the reactant more uniform, thereby reducing the generation of impurities.

The invention discloses a terbium-doped benzene polycarboxylic acid-metformin HOF material and application thereof in detection of an explosive precursor sodium hypochlorite, and belongs to the technical field of fluorescent probes and fluorescence detection. The terbium-doped benzene polycarboxylic acid-metformin HOF material is formed by coordination compounding of an HOF matrix and rare earth metal ions Tb < 3 + >, and the HOF matrix is formed by self-assembly of benzene polycarboxylic acid compounds and metformin hydrochloride through intermolecular hydrogen bonds. The material can generate high-selectivity fluorescence quenching response to sodium hypochlorite (NaClO) through characteristic fluorescence emission (5D4-7F5 transition) of Tb < 3 + > at 545nm, is low in detection limit and wide in linear range, and can be used for realizing rapid and high-sensitivity detection of low-concentration NaClO. And the method has great significance in blocking the synthesis of explosives based on NaClO.

The application belongs to the technical field of biological medicine, and more particularly relates to nanoparticles TK-PSBs / CBD@Met, a preparation method therefor and application thereof. The nanoparticles TK-PSBs / CBD@Met are nanoparticles formed by wrapping cannabidiol and metformin with thione-modified lung surfactant biomimetic liposomes. In vitro experiments have confirmed that the nanoparticles TK-PSBs / CBD@Met can effectively inhibit the fibrosis process of BEAS-2B cells induced by silicon dioxide. Animal experiments have shown that the nanoparticles TK-PSBs / CBD@Met can significantly improve the damage to the lung tissue structure and abnormal deposition of collagen caused by SiO2 exposure, and alleviate the pathological progression of silicosis fibrosis.

The invention discloses a gliquidone multilayer sustained-release tablet and a preparation method thereof, and belongs to the technical field of medical products, the gliquidone multilayer sustained-release tablet comprises a first tablet core and a second tablet core containing gliquidone, the first tablet core is coated with an isolation layer, and the isolation layer and the outer layer of the second tablet core are coated with an outer coating; the first tablet core comprises metformin, sodium bicarbonate, microcrystalline cellulose and resistant starch; the isolating layer comprises an enteric coating. The first tablet core is coated with the enteric coating, so that the dissolution property is greatly reduced under the acidic condition in the stomach, the stimulation of metformin to the stomach is reduced, and the comfort level of the stomach is improved; the metformin is gradually released in intestines; gliquidone is gradually released in gastrointestinal tracts, and is synergistically hypoglycemic with metformin; the resistant starch and the microcrystalline cellulose have a slow release effect, promote intestinal tract movement and improve the comfort of intestinal tracts; the sodium bicarbonate can absorb lactic acid rise caused by metformin accumulation.

The invention belongs to the technical field of biological medicines, and particularly relates to application of human umbilical cord mesenchymal stem cells combined with metformin in preparation of anti-DFU medicines. By constructing a diabetic foot ulcer rat model and combining in-vivo and in-vitro experiments and signal analysis, it is confirmed for the first time that hUC-MSCs and metformin have a synergistic effect in treating diabetic foot ulcer. Combined treatment is beneficial to diabetic foot ulcer wound closure, reepithelization, matrix remodeling and proliferation of blood vessels and inflammation related cells, regulation and control of vascular endothelial cells PI3K-AKT and downstream signal channels thereof can be promoted through paracrine, so that the inhibited survival, proliferation, migration and vascularization capacities of the vascular endothelial cells PI3K-AKT in a hyperglycemia environment are recovered, and the vascular endothelial cells PI3K-AKT and the downstream signal channels of the vascular endothelial cells PI3K-AKT are promoted. Further, the dynamic regulation of enhancement, maturation and weakening of new angiogenesis of the wound of the DFU rat is promoted, and the wound healing is accelerated. The invention provides theoretical basis and experimental support for developing a more effective treatment scheme.

This application provides a method for improving the mixing uniformity of a compound preparation of metformin and empagliflozin, belonging to the field of pharmaceutical technology. The invention provides a dry granulation and ultrasonic mixing method, which utilizes airflow pulverization, ultrasonically assisted vertical axis planetary mixer mixing, and forced sieving technology to enhance the process. The method utilizes the synergistic effect of ultrasound and the mixer to shorten mixing time, enhance mixing efficiency, and significantly improve the uniformity and dissolution rate of the preparation. This process is short, simple to operate, and easily controllable, making it suitable for large-scale production.